Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T17:06:21.713Z Has data issue: false hasContentIssue false
  • English
  • Français

Prognostic Factors in Oligodendroglioma

Published online by Cambridge University Press:  18 September 2015

D. Schiffer ,
A. Dutto ,
P. Cavalla ,
I. Bosone ,
A. Chiò ,
R. Villani  and
C. Bellotti
D. Schiffer*
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy
A. Dutto
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy
P. Cavalla
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy
I. Bosone
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy
A. Chiò
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy
R. Villani
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy Institute of Neurosurgery, University of Milan, Milan, Italy
C. Bellotti
Affiliation:
Department of Neuroscience, University of Turin, Turin, Italy Division of Neurosurgery, Ospedale Maggiore, Novara, Italy
*
Division of Neurology, Department of Neuroscience, via Cherasco, 15, 10126 Turin, Italy
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

A reliable marker for tumor oligodendroglial cells is not yet available, so that the histological recognition of the tumor still encounters uncertainties. There is no general agreement also on prognostic factors in oligodendroglioma. The inconsistency concerns mainly the histopathological factors. The aim of the study was recognition of prognostic factors in oligodendroglioma.

Methods:

In a series of ninety-eight oligodendrogliomas, including twenty mixed oligoastrocytomas, clinical [sex, age at surgery, tumor location, symptoms at presentation], therapeutic [extent of resection, year of surgery, post-operative Karnofsky score, post-operative radiotherapy, post-operative chemotherapy], histological [cell density, nuclear pleomorphism, vascular endothelial proliferation, necrosis, microcysts, mitoses, mitotic index (MI), apoptosis, apoptotic index (AI)] and immunohistochemical parameters [MIB-1 and PCNA Labeling Indexes (Lis), staining for GFAP, positivity for p53] were correlated with survival in uni- and multivariate analysis in order to identify their prognostic significance.

Results:

Age at surgery, extent of surgical resection, year of surgery, postoperative Karnofsky score and MIB-1 LI were associated with survival in both uni- and multivariate analysis. Location, symptoms at presentation, mitoses, MI, AI, and PCNA LI showed a significant correlation with survival in uni- but not in multivariate analysis. The twenty cases of oligoastrocytomas did not show any difference in survival from pure oligodendrogliomas.

Conclusions:

Some clinical and therapeutic factors together with MIB-1 LI play a prognostic role. MIB-1 LI is prognostic with a cutoff of 8%. Histology gives a limited contribution to the prognosis. Oligoastrocytomas had the same outcome and prognostic factors as pure oligodendrogliomas.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 4 , November 1997 , pp. 313 - 319
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

REFERENCES

1.Ziilch, KJ: Brain Tumours. Their Biology and Pathology. 3rd ed. Berlin-Heidelberg-New York-Tokyo: Springer, 1986.Google Scholar
2.Russell, DS and Rubinstein, LJ. Pathology of Tumours of the Nervous System. 5th ed. London: Arnold, 1989.Google Scholar
3.Cairncross, JG. and Macdonald, DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360–364.CrossRefGoogle ScholarPubMed
4.Glass, J, Hochberg, FH, Gruber, ML, et al. The treatment of oligodendrogliomas and mixed oligoendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992; 76: 741–745.CrossRefGoogle ScholarPubMed
5.Kyritsis, AP, Yung, WKA, Bruner, J, Gleason, MJ, Levin, VA. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993; 32: 365–371.CrossRefGoogle ScholarPubMed
6.Mason, WP, Krol, GS, De Angelis, LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46: 203–207.CrossRefGoogle ScholarPubMed
7.Smith, MT, Ludwig, CL, Godfrey, AD, Armbrustmacher, VW. Grading of oligodendrogliomas. Cancer 1983; 52: 2107–2114.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
8.Kros, JM, Pieterman, H, van Eden, CG, Avezaat, CJJ. Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 1994; 34: 959–966.Google ScholarPubMed
9.Kros, JM, Hop, WCJ, Godschalk, JCJ, Krishnadath, KK. Prognostic value of the proliferation-related antigen Ki–67 in oligodendrogliomas. Cancer 1996; 78: 1107–1113.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
10.Shaw, EG, Scheithauer, BW, O’Fallon, JR, Tazelaar, HD, Davis, DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992; 76: 428–434.CrossRefGoogle ScholarPubMed
11.Mørk, SJ, Halvorsen, TB, Lindegaard, K-F, Eide, GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986; 45: 65–78.CrossRefGoogle ScholarPubMed
12.Burger, PC, Rawlings, CE, Cox, EB, et al. Clinicopathologic correlations in the oligodendroglioma. Cancer 1987; 59: 1345–1352.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
13.Celli, P, Nofrone, I, Palma, L, Cantore, G, Fortuna, A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994;35: 1018–1035.CrossRefGoogle ScholarPubMed
14.Coons, SW and Johnson, PC. MIB-l/Ki–67 labeling index predicts patient survival for oligodendroglial tumors. J Neuropathol Exp Neurol 1995; 24: 9–12.Google Scholar
15.Heegard, S, Sommer, HM, Broholm, H, Broendstrup, O. Proliferating cell nuclear antigen and Ki–67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995; 76: 1809–1813.3.0.CO;2-I>CrossRefGoogle Scholar
16.Kleihues, P, Burger, PC, Scheithauer, BW. WHO. Histological Typing of Tumours of the Central Nervous System. 2nd ed. Berlin, Heidelberg, New York, etc. Springer, 1993, 19.CrossRefGoogle Scholar
17.Bullard, DE, Rawlings, CE, Phillips, B, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987; 60: 2179–2188.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
18.Nijjar, TS, Simpson, WJ, Gadalla, T, McCartney, M. Oligodendroglioma. The Princess Margaret Hospital Experience (1958–1984). Cancer 1993; 71: 4002–4006.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
19.Mørk, SJ, Lindergaard, K-F, Halvorsen, TB, et al. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985; 63: 881–889.CrossRefGoogle Scholar
20.Daumas-Duport, C, Scheithauer, BW, O’Fallon, J, Kelly, P. Grading of astrocytomas: a simple and reproducible grading method. Cancer 1988; 62: 2152–2165.3.0.CO;2-T>CrossRefGoogle Scholar
21.Migheli, A, Cavalla, P, Marino, S, Schiffer, D: A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994; 53: 606–616.CrossRefGoogle ScholarPubMed
22.Herpers, MJHM and Budka, H. Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol 1984; 64: 265–272.CrossRefGoogle ScholarPubMed
23.Schiffer, D, Chiò, A, Giordana, MT, Pezzulo, T, Vigliani, MC. Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol 1993; 85: 495–502.CrossRefGoogle ScholarPubMed
24.Kaplan, EL and Meier, P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481.CrossRefGoogle Scholar
25.Segal, MR. Regression trees for censored data. Biometrics 1988; 44: 35–47.CrossRefGoogle Scholar
26.Peto, R, Pike, MG, Armitage, P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: analysis and examples. Br J Cancer 1977; 35: 1–39.CrossRefGoogle ScholarPubMed
27.Cox, DR. Regression models and life tables. J R Stat Soc 1972; B34: 187–220.Google Scholar
28.Earnest, F, Kernohan, JW, Craig, WMcK. Oligodendrogliomas: a review of two hundred cases. Arch Neurol Psychiat 1950; 63: 964–976.CrossRefGoogle Scholar
29.Kernohan, JW. Oligodendrogliomas. In: Minckler, J, ed. Pathology of the Nervous System. Vol 2, New York: Mc Graw-Hill, 1971: 1993–2007.Google Scholar
30.Weir, B, Elvidge, AR. Oligodendrogliomas: an analysis of 60 cases. J Neurosurg 1968; 29: 500–505.CrossRefGoogle Scholar
31.Kernohan, JW, Mabon, RF, Svien, HJ, Adson, AW. A simplified classification of the gliomas. Proc Staff Meet Mayo Clinic 1949; 24: 71–75.Google ScholarPubMed
32.Schiffer, D, Cavalla, P, Pilkington, GJ. Proliferative properties of malignant brain tumors. In: Mikkelsen, T, Bjerkvig, R, Laerum, O and Rosemblum, ML, eds. Brain Tumor Invasion: Biological Clinical and Therapeutic considerations. John Wiley and Sons Inc, 1996.Google Scholar
33.Schiffer, D, Cavalla, P, Migheli, A, Chid, A, Giordana, MT. Apoptosis and cell proliferation in neuroepithelial tumors. Neurosci Lett 1995; 195:81–84.CrossRefGoogle ScholarPubMed
34.Lipponen, PK and Aaltomaa, S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 173: 333–339.CrossRefGoogle ScholarPubMed
35.Ellison, DW, Steart, PV, Gatter, KC, Weller, RO. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995; 21: 352–361.CrossRefGoogle ScholarPubMed
36.Khoshyomn, S, Maier, H, Morimura, T, Kitz, K, Budka, H. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 1993; 86: 582–589.CrossRefGoogle ScholarPubMed
37.Karamitopoulou, E, Perentes, E, Melachrinou, M, Maraziotis, T. Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms. Acta Neuropathol 1993; 85: 316–322.CrossRefGoogle ScholarPubMed
38.Shaw, EG, Scheithauer, BW, O’Fallon, JR, Davis, DH. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994; 34: 577–582.Google ScholarPubMed
39.de la Monte, SM. Uniform lineage of oligodendrogliomas. Am J Pathol 1989; 135: 529–540.Google ScholarPubMed
40.Bishop, M and de la Monte, SM. Dual lineage of astrocytomas. Am J Pathol 1989; 135: 517–527.Google ScholarPubMed
41.von Diemling, A, Louis, DN, von Ammon, K, et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytoma, oligodendroglioma and mixed glioma. Cancer Res 1992; 52: 4277–4279.Google Scholar
42.Reifenberger, J, Reifenberger, G, Liu, L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19qand lp. Am J Path 1994; 145: 1175–1189.Google Scholar
43.Kraus, JA, Koopman, J, Kaskel, P, et al. Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91–95.CrossRefGoogle Scholar
44.Kros, JM, Godschalk, JJCJ, Krishnadath, KK, van Eden, CG. Expression of p53 in oligodendrogliomas. J Pathol 1993; 171: 285–290.CrossRefGoogle ScholarPubMed
45.Pavelic, J, Hlavka, V, Poljak, M, Gale, N, Pavelic, K. p53 immunoreactivity in oligodendrogliomas. J Neuro-Oncol 1994; 22: 1–6.CrossRefGoogle ScholarPubMed
46.Wu, JK, Zhen, Y, Darras, BT. Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery 1993;33:824–831.Google ScholarPubMed
47.Louis, DN, von Deimling, A, Chung, RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumours. J Neuropathol Exp Neurol 1993; 52: 31–38.CrossRefGoogle Scholar
48.Wallner, KE, Gonzales, M, Sheline, GE. Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 1988; 68: 684–688.CrossRefGoogle ScholarPubMed